Please try another search
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for hypertension, diabetes, hypercholesterolemia, gastrointestinal care, and pediatric care, as well as peritoneal dialysis solution. It also provides injections for acute craniocerebral trauma, viral pneumonia and bronchitis, infectious diseases, calcium deficiency, metabolic acidosis, vitamin B and C deficiency, chronic severe pain, drug-resistant bacteria, and hypovolemia. In addition, the company offers pharmaceutical raw materials; pharmaceutical equipment comprising aluminum-plastic blister packaging machine and multifunctional cartoning machine. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of China Resources Pharmaceutical Group Limited.
Name | Age | Since | Title |
---|---|---|---|
Zhanfeng Yang | - | - | Director |
Ning Liu | 65 | 2021 | Independent Director |
Jun Wu | 60 | 2012 | Chairman of the Supervisory Board |
Maozhu Sun | 64 | 2021 | Independent Director |
Zheng Wei | 62 | 2018 | Independent Director |
Wenchao Lu | 46 | 2022 | President & Director |
Cailian Kang | 48 | 2018 | Independent Director |
Xiangming Li | 58 | 2021 | Director |
Xiaosong Bai | 52 | 2022 | Director |
Guolong Lin | - | 2023 | Director |
Hui Xu | - | 2023 | Director |
Ran Tao | 59 | 2019 | Member of Supervisory Board |
Lili Yan | 49 | 2016 | Employee Supervisor |
Wei Sang | 45 | 2021 | Employee Supervisor |
Na Tang | 47 | 2021 | Supervisor |
Shutian Yu | 57 | 2022 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review